|
|
Presented by Dr. Alan G. Waxman, MD, MPH
Release Date of Activity: December 2009
Expiration Date of Activity for AMA PRA Credit: December 31, 2012
Estimated Time to Complete This Activity: 1 hour
Authors and Reviewers Biosketches |
To register for the Online CME Series click here
A quadrivalent human papillomavirus (HPV) vaccine has been available since 2006 offering protection against HPV types 6, 11, 16, and 18. In October 2009, the U.S. Food and Drug Administration approved a second, bivalent, vaccine against HPV types 16 and 18. HPV types 16 and 18 are known to be the etiologic agent in approximately two-thirds to three-quarters of cervical cancers. These viral types are also implicated in other lower genital tract cancers. An effective vaccine therefore has the potential to prevent significant suffering and mortality worldwide.
This continuing medical education activity will review those aspects of the biology, epidemiology, and natural history of HPV that have led to the development of vaccines and directed immunization guidelines. The program will help providers identify which patients are most likely to benefit from vaccination against human papillomavirus and answer questions commonly asked by patients and their family members, colleagues and the public about the HPV vaccine. This CME activity also reviews recent efficacy studies of both HPV vaccines and examines immunization-associated adverse events reported to the FDA. Cost effectiveness of HPV vaccination is also addressed as are some frequently asked questions about the vaccines.
Competencies and Objectives
The Targeting Cervical Cancer with the HPV Vaccines program has been primarily designed to improve knowledge-based competencies, as well as performance gap patterns, as to the appropriate usages and limitations HPV vaccination. Completion of this module will prepare the participant to:
- understand the biology, epidemiology, and natural history of human papillomavirus (HPV) that have permitted the development of vaccines and have directed immunization guidelines (medical knowledge);
- identify patients most likely to benefit from vaccination against HPV (practice-based learning, patient care);
- discuss the efficacy, benefits and risks associated with HPV vaccination (medical knowledge, patient care, interpersonal and communication skills); and,
- review the cost effectiveness of HPV vaccination (medical knowledge, systems-based practice, practice-based learning).
Is this educational activity right for me?
The Targeting Cervical Cancer with the HPV Vaccines CME program will best serve those licensed physicians and advanced practice clinicians who will be counseling about and prescribing HPV vaccines. These include clinicians who make gynecologic diagnosis and management decisions or who provide clinical or consultative primary care for female adolescents and women aged 21 and older, especially clinicians in the fields of family medicine, obstetrics and gynecology, and pediatrics. Consequently, this activity has been developed for the gynecologist, family physician, gynecologic oncologist, advanced practice clinician (e.g., NP, CNM, PA-C), pathologist, pediatrician, and resident working with women and adolescents and counseling them about and prescribing HPV vaccines.
ACCME Accreditation
The American Society for Colposcopy and Cervical Pathology (ASCCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Continuing Medical Education Credits
The ASCCP designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Notice of Contributed Funds/Commercial Support
The Targeting Cervical Cancer with the HPV Vaccines course was produced specifically through grants received in 2005-06 from Merck & Company, GlaxoSmithKline, Digene Corporation (now Qiagen), and Roche. All other lectures in this Series were developed and produced free of commercial support.
Management of Conflicts of Interest and Contributed Funds
As an accredited provider of CME credit, ASCCP is required to comply with the ACCME's Standards for Commercial Support and has implemented a management process to ensure that anyone who is in a position to affect the content of the educational activity (e.g., faculty, planners, etc.) has disclosed to us all relevant financial relationships with any commercial interest and has ensured that those relationships do not influence presentation materials. All faculty have agreed to base their presentations on best available evidence. ASCCP discloses to learners any financial relationship(s) to healthcare-related commercial interests existing within the past 12 months to include the following information: 1) the name of the individual; 2) the name of the commercial interest; and, 3) the nature of the relationship the person has with each commercial interest. Slides and slide notes are reviewed for possible bias prior to the activity's release by the Accreditation Committee and peer-reviewers, and potential conflicts of interest are resolved prior to the live presentation. Any discussion of off-label use of products is noted when appropriate, as is discussion of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Disclosures of these commitments and/or relationships are published in these lecture materials and provided prior to the start of the activity, so the learners may formulate their own judgments regarding the presentation(s). Under ASCCP policy, anyone declining either to disclose or amend material to eliminate potential bias identified by the Accreditation Committee will be replaced.
Author, Reviewers, and Planners' Disclosure Information
The following are all reported disclosures of interest or potential conflicts from the 12 months preceding this activity:
J. Thomas Cox, MD (Project Editor) - serves on the Data and Safety Monitoring Board for Merck & Co and receives a fee for his service. He is also a scientific advisory board member for Gen-Probe and an advisory board member for Abbott, for both of which he receives an honorarium.
Diane Solomon, MD (CME Reviewer) - serves as a Medical Monitor for the National Cancer Institute's HPV Vaccine Trial in Costa Rica: the trial receives vaccine from GlaxoSmithKline.
Those reporting no financial relationships or conflict of interest to disclose:
Alan G. Waxman, MD, MPH (Author)
L. Stewart Massad, MD (Accreditation Committee Co-chair/CME Reviewer/Planner)
Herschel W. Lawson, MD (CME Reviewer/Accreditation Committee Co-chair)
Kathleen Poole (ASCCP Executive Director, Planner)
Carol Noonan (ASCCP Assistant Course Administrator, Planner)
CME Inquiries
For all CME certificate inquiries, please contact Ms. Carol Noonan at cnoonan@asccp.org or by mail at the ASCCP National Office, 152 West Washington Street, Hagerstown, MD 21740 or by phone at 301-733-3640.
|